JP2023530277A - バキュロウイルス発現系 - Google Patents

バキュロウイルス発現系 Download PDF

Info

Publication number
JP2023530277A
JP2023530277A JP2022576003A JP2022576003A JP2023530277A JP 2023530277 A JP2023530277 A JP 2023530277A JP 2022576003 A JP2022576003 A JP 2022576003A JP 2022576003 A JP2022576003 A JP 2022576003A JP 2023530277 A JP2023530277 A JP 2023530277A
Authority
JP
Japan
Prior art keywords
anellovirus
nucleic acid
orf1
sequence
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022576003A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530277A5 (cg-RX-API-DMAC10.html
Inventor
サイモン デラグレイブ,
ジャレド デイビッド ピッツ,
Original Assignee
フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド filed Critical フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド
Publication of JP2023530277A publication Critical patent/JP2023530277A/ja
Publication of JP2023530277A5 publication Critical patent/JP2023530277A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022576003A 2020-06-12 2021-06-11 バキュロウイルス発現系 Pending JP2023530277A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063038603P 2020-06-12 2020-06-12
US63/038,603 2020-06-12
US202163147056P 2021-02-08 2021-02-08
US63/147,056 2021-02-08
PCT/US2021/037076 WO2021252943A2 (en) 2020-06-12 2021-06-11 Baculovirus expression systems

Publications (2)

Publication Number Publication Date
JP2023530277A true JP2023530277A (ja) 2023-07-14
JP2023530277A5 JP2023530277A5 (cg-RX-API-DMAC10.html) 2024-06-18

Family

ID=78845950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022576003A Pending JP2023530277A (ja) 2020-06-12 2021-06-11 バキュロウイルス発現系

Country Status (12)

Country Link
US (1) US20230340527A1 (cg-RX-API-DMAC10.html)
EP (1) EP4164667A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023530277A (cg-RX-API-DMAC10.html)
KR (1) KR20230036109A (cg-RX-API-DMAC10.html)
CN (1) CN116034160A (cg-RX-API-DMAC10.html)
AU (1) AU2021288051A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022025221A2 (cg-RX-API-DMAC10.html)
CA (1) CA3186872A1 (cg-RX-API-DMAC10.html)
IL (1) IL298906A (cg-RX-API-DMAC10.html)
MX (1) MX2022015801A (cg-RX-API-DMAC10.html)
TW (1) TW202239762A (cg-RX-API-DMAC10.html)
WO (1) WO2021252943A2 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3121528A1 (en) 2018-12-12 2020-06-18 Flagship Pioneering Innovations V, Inc. Anellosomes and methods of use
CA3206361A1 (en) * 2020-12-23 2022-06-30 Flagship Pioneering Innovations V, Inc. In vitro assembly of anellovirus capsids enclosing rna
WO2022170195A1 (en) * 2021-02-08 2022-08-11 Flagship Pioneering Innovations V, Inc. Hybrid aav-anellovectors
TW202334423A (zh) 2021-12-15 2023-09-01 美商旗艦先鋒創新公司 表面經修飾之病毒顆粒及模組化之病毒顆粒
TW202529819A (zh) 2023-10-13 2025-08-01 美商旗艦先鋒創新公司 組織特異性指環載體(anellovector)遞送
CN117305365B (zh) * 2023-11-28 2024-03-19 中国科学院生物物理研究所 昆虫细胞—哺乳动物细胞表达穿梭载体SmartBM-1及其应用
WO2025160409A1 (en) 2024-01-26 2025-07-31 Flagship Pioneering Innovations V, Inc. Viral vectors for modulating vegf function

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502229A (ja) * 2009-08-21 2013-01-24 ヴァージニア テック インテレクチュアル プロパティーズ,インコーポレーテッド 豚トルクテノウイルスワクチンおよび診断
JP2013507918A (ja) * 2009-10-16 2013-03-07 ファイザー・インク トルクテノウイルスの感染性クローン
WO2018232017A1 (en) * 2017-06-13 2018-12-20 Flagship Pioneering, Inc. Compositions comprising curons and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101320192B1 (ko) * 2008-10-16 2013-10-30 조에티스 엘엘씨 토크 테노 바이러스(ttv) 분리물 및 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502229A (ja) * 2009-08-21 2013-01-24 ヴァージニア テック インテレクチュアル プロパティーズ,インコーポレーテッド 豚トルクテノウイルスワクチンおよび診断
JP2013507918A (ja) * 2009-10-16 2013-03-07 ファイザー・インク トルクテノウイルスの感染性クローン
WO2018232017A1 (en) * 2017-06-13 2018-12-20 Flagship Pioneering, Inc. Compositions comprising curons and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FEMS MICROBIOLOGY REVIEWS, vol. 44, JPN6025019921, March 2020 (2020-03-01), pages 305 - 313, ISSN: 0005595994 *
NATURE COMMUNICATIONS, vol. 7:13014, JPN6025019923, 2016, ISSN: 0005595992 *
VIROLOGY, vol. 381, JPN6025019922, 2008, pages 36 - 45, ISSN: 0005595993 *

Also Published As

Publication number Publication date
TW202239762A (zh) 2022-10-16
CN116034160A (zh) 2023-04-28
CA3186872A1 (en) 2021-12-16
EP4164667A2 (en) 2023-04-19
WO2021252943A3 (en) 2022-01-20
BR112022025221A2 (pt) 2023-03-07
KR20230036109A (ko) 2023-03-14
EP4164667A4 (en) 2024-10-23
IL298906A (en) 2023-02-01
AU2021288051A1 (en) 2023-01-19
US20230340527A1 (en) 2023-10-26
WO2021252943A2 (en) 2021-12-16
MX2022015801A (es) 2023-05-19

Similar Documents

Publication Publication Date Title
US20220362315A1 (en) Anellovirus compositions and methods of use
JP2023010961A (ja) クロンを含む組成物及びその使用
JP2024100936A (ja) 分泌治療モダリティを送達するためのアネロソーム
US20220042042A1 (en) Anellosomes and methods of use
AU2019396516B2 (en) Anellosomes for delivering intracellular therapeutic modalities
EP4164667A2 (en) Baculovirus expression systems
WO2020123795A2 (en) Anellosomes for delivering protein replacement therapeutic modalities
JP2023530278A (ja) タンデムアネロウイルス構築物
US12540337B2 (en) Surface-modified viral particles and modular viral particles
JP2023530451A (ja) アネロウイルスを同定し及び特徴付ける方法並びにその使用
JP2024507732A (ja) ハイッブリッドaav-アネロベクター
JP2024501287A (ja) RNAを閉じ込めたアネロウイルス(Anellovirus)キャプシドのインビトロアセンブリ
JP2025517327A (ja) 修飾アネロウイルスカプシドタンパク質を含む組成物及びその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240610

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250519

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251107